Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Spyratos (Thessaloniki, Greece). Immunotherapy with nivolumab in NSCLC: single center experience after one year clinical practice. 4228

Member's Comments

No comment yet.

Related content which might interest you: Clinical trials in advanced stage lung cancer: A survey of patients‘ opinion about their treatment Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 A single centre review of palliative chemotherapy in newly diagnosed stage IIIb and IV lung cancer patients with good performance status Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective Source: Eur Respir Monogr 2015; 68: 178-185 Year: 2015 Trends of the proportion of small-cell lung cancer (SCLC) over the last 20 year: a university medical center experience Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Survival with in-operable non-small cell lung cancer in U.K district general hospital: Is chemotherapy better than active supportive care? Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Study of patient nominated symptoms and changing symptamatology in patients with lung cancer receiving palliative chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 323s Year: 2005 Bronchioloalveolar adenocarcinoma: clinical features and outcome over a eleven year period – a single centre experience Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Drug development: news from “hot” early stage clinical trials: personalised immunotherapy for lung cancer Source: International Congress 2017 – Scientific year in review Year: 2017 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience Source: Eur Respir J 2003; 22: Suppl. 45, 32s Year: 2003 Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 The proportion of EGFR+ NSCLC patients never treated with TKI – A single institution Croatian experience Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Approaches in patients with locally advanced NSCLC: a surgeon's perspective Source: Eur Respir Monogr 2015; 68: 167-177 Year: 2015